These findings indicate that the antitumor effect of gefitinib is more effective for reducing prostate tumors in a hormone-depleted environment than for those where hormone is present, further demonstrating that the hormone-independent proliferation of CRPC is dependent on EGFR signaling. Here, EGFR is linked to prostate neoplasm.